Sorafenib is an inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptors; the recommended dose is 400 mg twice daily; dose-limiting toxicities include diarrhoea, fatigue and skin toxicity (Strumberg et al, 2005). The gene discussed is VEGFA; the disease is neoplasm.